John Stratton - Abbott Laboratories Director

ABT Stock  MXN 1,845  45.01  2.50%   

Director

Mr. John G. Stratton is Director of the Company since 2017.
Age 57
Tenure 7 years
Phone224 667 6100
Webhttps://www.abbott.com
Stratton has served as Executive Vice President and President of Global Operations since February 2015. Previously, he served as Executive Vice President and President of Global Enterprise and Consumer Wireline from April 2014 to February 2015, as President of Verizon Enterprise Solutions from January 2012 to April 2014, and as Chief Operating Officer and Executive Vice President of Verizon Wireless from October 2010 to January 2012. Since October 2012, Mr. Stratton has also served as a member of The President National Security Telecommunications Advisory Committee. Through his executive leadership at Verizon Communications, Mr. Stratton contributes extensive business and management experience operating a global public company such as Abbott, including valuable insights on corporate strategy and risk management. His service on the National Security Telecommunications Advisory Committee enables him to provide government perspective and experience in a highly regulated industry.

Abbott Laboratories Management Efficiency

The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 17.3 B in total debt with debt to equity ratio (D/E) of 64.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abbott Laboratories has a current ratio of 1.55, which is within standard range for the sector. Debt can assist Abbott Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Abbott Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbott Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbott to invest in growth at high rates of return. When we think about Abbott Laboratories' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Rafael AnciolaSouthern Copper
57
Indira SamarasekeraThe Bank of
65
David NicholsonLloyds Banking Group
N/A
Jennifer TippinLloyds Banking Group
N/A
Scott BonhamThe Bank of
56
Michael PennerThe Bank of
48
Melanie HealeyVerizon Communications
56
Peter BonfieldTaiwan Semiconductor Manufactur
74
Benita WarmboldThe Bank of
59
Ronald BrennemanThe Bank of
69
Juan ColombasLloyds Banking Group
N/A
Reynold LevyFirst Republic Bank
71
Michael SteinMcEwen Mining
65
George ParkerFirst Republic Bank
78
Luis BonillaSouthern Copper
58
Richard RexachVerizon Communications
63
Paul SobeyThe Bank of
58
Alfredo PerezSouthern Copper
65
Donald NicolaisenVerizon Communications
70
Toby StraussLloyds Banking Group
N/A
Eduardo CortesThe Bank of
64
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company was founded in 1888 and is headquartered in Abbott Park, Illinois. ABBOTT LABORATORIES operates under Medical Devices classification in Mexico and is traded on Mexico Stock Exchange. It employs 103000 people. Abbott Laboratories (ABT) is traded on Mexican Exchange in Mexico and employs 115,000 people.

Management Performance

Abbott Laboratories Leadership Team

Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott White, Senior Vice President - International Nutrition
Samuel Scott, Independent Director
Deepak Nath, Senior Vice President - Abbott Vascular
Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Mary Moreland, Ex HR
Roger Bird, Senior Vice President - U.S. Nutrition
Nancy McKinstry, Independent Director
Heather Mason, Senior Vice President - Abbott Diabetes Care
James Farrell, Independent Director
Phebe Novakovic, Independent Director
JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets
Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Roxanne Austin, Independent Director
Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Stephen Fussell, Executive Vice President - Human Resources
Thomas Freyman, Executive VP of Fin. and Admin.
Sally Blount, Independent Director
Daniel Starks, Independent Director
Michelle Kumbier, Director
Thomas Frinzi, Senior Vice President - Abbott Medical Optics
Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation
John Capek, Executive VP of Ventures
Robert Alpern, Independent Director
Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics
Miles White, Chairman, CEO and Chairman of Executive Committee
Robert Ford, Senior Vice President Diabetes Care.
Glenn Tilton, Independent Director
Elaine Leavenworth, VP Officer
Richard Ashley, Executive VP of Corporate Devel.
Michael Rousseau, President - Cardiovascular and Neuromodulation
Edward Liddy, Independent Director
Hubert Allen, Executive VP, General Counsel and Secretary
Charles Foltz, Senior Vice President - Abbott Vascular
Brian Yoor, CFO and Sr. VP of Fin.
John Stratton, Director
Joseph Manning, Senior Vice President - Abbott Nutrition International
Scott Leinenweber, Licensing Relations
James Young, VP Officer
Jared Watkin, Senior Vice President - Diabetes Care
William Osborn, Independent Director
Brian Blaser, Executive VP of Diagnostic Products
Michael Warmuth, Executive Vice President - Established Pharmaceuticals
Robert Funck, Vice President Controller
Daniel Salvadori, Senior Vice President Established Pharmaceuticals, Latin America.
Andrea Wainer, Ex Diagnostics
Melissa Brotz, VP Marketing

Abbott Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Abbott Laboratories

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.

Moving against Abbott Stock

  0.85TMN Toyota MotorPairCorr
  0.68SMSNN Samsung ElectronicsPairCorr
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock. Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Abbott Stock analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Fundamental Analysis
View fundamental data based on most recent published financial statements
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.